Home » FDA Puts Clinical Hold on CRISPR, Vertex Sickle Cell Treatment IND
FDA Puts Clinical Hold on CRISPR, Vertex Sickle Cell Treatment IND
Drugs Inspections and Audits
The FDA placed a clinical hold on CRISPR Therapeutics and Vertex’s IND for treatment of sickle cell disease.
The companies submitted the IND to the agency in April. The hold will remain in place until unspecified questions are resolved to the FDA’s satisfaction.
The companies said they expect the agency to provide further information on its questions in the near future.